Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | $99M | $83M | $-2M | 53.8% | 350.9% | -178.9% |
| 2024 | $24M | $-76M | $-106M | $-70M | -266.0% | -14.0% | 129.1% |
| 2023 | $27M | $-44M | $-46M | $-34M | -74.4% | 170.3% | 72.0% |
| 2022 | $10M | $-26M | $-27M | $-19M | -35.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 10.16 | 27.46 | 23.61 | 106.47 |
| Operating Revenue | - | 10.16 | 27.46 | 23.61 | 106.47 |
| Cost Of Revenue | - | 0.22 | 2.17 | 7.42 | 16.48 |
| Gross Profit | - | 9.94 | 25.29 | 16.20 | 89.99 |
| Operating Expense | - | 34.84 | 74.89 | 103.20 | 94.22 |
| Research And Development | - | 19.80 | 39.81 | 42.10 | 12.74 |
| Selling General And Administration | - | 15.04 | 34.31 | 54.87 | 77.62 |
| Total Expenses | - | 35.06 | 77.06 | 110.62 | 110.70 |
| Operating Income | - | -24.90 | -49.60 | -87 | -4.23 |
| Total Operating Income As Reported | - | -42.56 | -49.60 | -87 | -62.94 |
| EBITDA | - | -25.53 | -43.54 | -76.40 | 98.71 |
| Normalized EBITDA | - | -22.44 | -44.06 | -78.44 | 6.77 |
| EBIT | - | -26.47 | -44.55 | -82.79 | 94.66 |
| Interest Income | - | 1.51 | 4.54 | 2.17 | 6.95 |
| Interest Expense | - | 0.34 | 1.50 | 7.35 | 7.98 |
| Net Interest Income | - | 1.18 | 3.04 | -5.18 | -1.03 |
| Other Income Expense | - | -3.08 | 0.52 | 2.04 | 91.94 |
| Interest Income Non Operating | - | 1.51 | 4.54 | 2.17 | 6.95 |
| Interest Expense Non Operating | - | 0.34 | 1.50 | 7.35 | 7.98 |
| Net Non Operating Interest Income Expense | - | 1.18 | 3.04 | -5.18 | -1.03 |
| Pretax Income | - | -26.80 | -46.05 | -90.14 | 86.68 |
| Tax Provision | - | -0.03 | 0 | 15.37 | 3.45 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0.43 | 3.66 |
| Net Income Continuous Operations | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income From Continuing And Discontinued Operation | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income From Continuing Operation Net Minority Interest | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income Common Stockholders | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Net Income Including Noncontrolling Interests | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Normalized Income | - | -23.69 | -46.56 | -107.12 | -5.05 |
| Diluted NI Availto Com Stockholders | - | -26.77 | -46.05 | -105.51 | 83.23 |
| Basic Average Shares | - | 34.49 | 35.45 | 46.25 | 55.31 |
| Diluted Average Shares | - | 34.49 | 35.45 | 46.25 | 57.26 |
| Reconciled Depreciation | - | 0.94 | 1.01 | 6.39 | 4.05 |
| Reconciled Cost Of Revenue | - | 0.22 | 1.94 | 7.26 | 16.29 |
| Total Unusual Items | - | -3.08 | 0.52 | 2.04 | 91.94 |
| Total Unusual Items Excluding Goodwill | - | -3.08 | 0.52 | 2.04 | 91.94 |
| Special Income Charges | - | -17.66 | 0 | 0 | 89.62 |
| Other Special Charges | 16.10 | 17.66 | - | - | - |
| Impairment Of Capital Assets | - | - | - | 0 | 58.71 |
| Restructuring And Mergern Acquisition | 0 | - | - | - | - |
| Gain On Sale Of Security | - | 14.58 | 0.52 | 2.04 | 2.33 |
| Depreciation Amortization Depletion Income Statement | - | - | 0.77 | 6.24 | 3.86 |
| Depreciation And Amortization In Income Statement | - | - | 0.77 | 6.24 | 3.86 |
| General And Administrative Expense | 8.70 | 15.34 | - | - | - |
| Other Gand A | 8.70 | 15.34 | - | - | - |
| Gain On Sale Of Ppe | - | - | - | 0 | 148.32 |
| Total Other Finance Cost | 0.15 | - | - | - | - |
| Otherunder Preferred Stock Dividend | 54.34 | 0 | - | - | - |
| Amortization | - | - | 0.77 | 6.24 | 3.86 |
| Amortization Of Intangibles Income Statement | - | - | 0.77 | 6.24 | 3.86 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Zevra Therapeutics, Inc.this co. | ZVRA | $660M | 7.93 | 4.27 | 53.8% | 6.70 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| SI-BONE, Inc. | SIBN | $660M |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 3.72 |
| -10.6% |
| - |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Peer Median | - | -9.63 | 3.44 | -37.3% | -3.17 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jun has averaged the highest return (+9.1%); Mar the lowest (-7.3%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.4%Neutral MonthJan 2026: +0.45% | -0.8%Neutral MonthFeb 2026: -0.78% | +4.4%Positive MonthMar 2026: +4.37% | +9.1%Positive MonthApr 2026: +9.12% | +14.0%Positive MonthMay 2026: +13.96% | +23.7%Positive MonthJun 2026: +23.73% | -33.7%Negative MonthJul 2026: -33.68% | +27.5%*Positive MonthAug 2026: +27.55% | — | — | — | — |
| 2025 | -6.0%Negative MonthJan 2025: -6.00% | +2.2%Positive MonthFeb 2025: +2.17% | -6.5%Negative MonthMar 2025: -6.49% | -2.1%Negative MonthApr 2025: -2.14% | +16.6%Positive MonthMay 2025: +16.64% | +3.0%Positive MonthJun 2025: +3.04% | +26.1%Positive MonthJul 2025: +26.11% | -18.4%Negative MonthAug 2025: -18.36% | +4.9%Positive MonthSep 2025: +4.85% | +7.0%Positive MonthOct 2025: +7.05% | -17.2%Negative MonthNov 2025: -17.19% | +6.3%Positive MonthDec 2025: +6.29% |
| 2024 | -11.6%Negative MonthJan 2024: -11.60% | +16.4%Positive MonthFeb 2024: +16.41% | -13.9%Negative MonthMar 2024: -13.95% | -21.0%Negative MonthApr 2024: -21.03% | +1.5%Neutral MonthMay 2024: +1.53% | +5.4%Positive MonthJun 2024: +5.38% | +32.4%Positive MonthJul 2024: +32.45% | +17.9%Positive MonthAug 2024: +17.87% | -9.3%Negative MonthSep 2024: -9.28% | +17.4%Positive MonthOct 2024: +17.44% | +14.5%Positive MonthNov 2024: +14.48% | -10.6%Negative MonthDec 2024: -10.61% |
| 2023 | +19.0%Positive MonthJan 2023: +18.95% | +6.4%Positive MonthFeb 2023: +6.41% | -5.3%Negative MonthMar 2023: -5.34% | -1.8%Neutral MonthApr 2023: -1.82% | -6.7%Negative MonthMay 2023: -6.67% | +1.2%Neutral MonthJun 2023: +1.19% | -4.3%Negative MonthJul 2023: -4.31% | +3.9%Positive MonthAug 2023: +3.89% | -4.9%Negative MonthSep 2023: -4.93% | -7.1%Negative MonthOct 2023: -7.05% | +6.3%Positive MonthNov 2023: +6.25% | +37.6%Positive MonthDec 2023: +37.61% |
| 2022 | -17.2%Negative MonthJan 2022: -17.22% | -17.8%Negative MonthFeb 2022: -17.75% | -15.2%Negative MonthMar 2022: -15.18% | -11.1%Negative MonthApr 2022: -11.13% | +3.6%Positive MonthMay 2022: +3.58% | -3.7%Negative MonthJun 2022: -3.67% | +25.6%Positive MonthJul 2022: +25.56% | -2.5%Negative MonthAug 2022: -2.50% | +14.3%Positive MonthSep 2022: +14.29% | -10.3%Negative MonthOct 2022: -10.26% | -15.0%Negative MonthNov 2022: -15.00% | -3.6%Negative MonthDec 2022: -3.57% |
| 2021 | — | — | — | — | +5.2%Positive MonthMay 2021: +5.24% | +25.2%Positive MonthJun 2021: +25.20% | -21.3%Negative MonthJul 2021: -21.29% | -7.8%Negative MonthAug 2021: -7.83% | +0.3%Neutral MonthSep 2021: +0.32% | +1.8%Neutral MonthOct 2021: +1.82% | -17.6%Negative MonthNov 2021: -17.58% | +11.2%Positive MonthDec 2021: +11.24% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
